PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab.

[1]  P. Schneider,et al.  RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. , 2013, Cancer research.

[2]  K. Gelmon,et al.  Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. , 2012, Current oncology.

[3]  J. Wysolmerski.  Parathyroid hormone-related protein: an update. , 2012, The Journal of clinical endocrinology and metabolism.

[4]  Gurmit Singh,et al.  PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone , 2012, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[5]  W. Schmiegel,et al.  A Rare Case of Chronic Lymphocytic Leukemia with Hypercalcemia Induced by Elevated Parathyroid Hormone-Related Peptides , 2010, Acta Haematologica.

[6]  E. Barbarotto,et al.  Role of the RANKL/RANK system in the induction of interleukin‐8 (IL‐8) in B chronic lymphocytic leukemia (B‐CLL) cells , 2006, Journal of cellular physiology.

[7]  A. F. Stewart.  Hypercalcemia Associated with Cancer , 2005 .

[8]  B. Leyland-Jones.  Treatment of cancer-related hypercalcemia: the role of gallium nitrate. , 2003, Seminars in oncology.

[9]  D. Meseure,et al.  Hypercalcaemia in B cell chronic lymphocytic leukaemia , 1994, British journal of haematology.

[10]  B. Schöttker,et al.  Parathyroid-hormone-related-protein-associated hypercalcemia in a patient with CLL-type low-grade leukemic B-cell lymphoma. , 2006, Haematologica.

[11]  P. Pauwels,et al.  Parathyroid hormone-related protein (PTH-rP)-associated hypercalcemia in a patient with an atypical chronic lymphocytic leukemia. , 1999, The Netherlands journal of medicine.